Cargando…
Radiomics of Tumor Heterogeneity in (18)F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer
SIMPLE SUMMARY: Biomarkers reliably predicting treatment response to immune checkpoint inhibition (CKI) therapy in advanced non-small cell lung cancer (NSCLC) are warranted. Baseline (18)F-FDG-PET-CT (PET-CT) is an integral part of the diagnostic algorithm of NSCLC. However, there is poor evidence o...
Autores principales: | Ventura, David, Schindler, Philipp, Masthoff, Max, Görlich, Dennis, Dittmann, Matthias, Heindel, Walter, Schäfers, Michael, Lenz, Georg, Wardelmann, Eva, Mohr, Michael, Kies, Peter, Bleckmann, Annalen, Roll, Wolfgang, Evers, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136892/ https://www.ncbi.nlm.nih.gov/pubmed/37190228 http://dx.doi.org/10.3390/cancers15082297 |
Ejemplares similares
-
(18)F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
por: Roll, Wolfgang, et al.
Publicado: (2021) -
Respiratory motion correction in F-18-FDG PET/CT impacts lymph node assessment in lung cancer patients
por: Noto, Benjamin, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitor-Associated Myocarditis: A Run of Bad Luck or Rather Deficient-Monitoring Protocol?
por: Chatzantonis, Grigorios, et al.
Publicado: (2020) -
Liquid Biopsies in Lung Cancer
por: Kemper, Marcel, et al.
Publicado: (2023) -
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report
por: Krekeler, Carolin, et al.
Publicado: (2023)